Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Stevanato Group S.p.A. (NYSE:STVN) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company.

Several equities research analysts have weighed in on the stock. Morgan Stanley reissued an “equal weight” rating and set a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Wolfe Research assumed coverage on shares of Stevanato Group in a report on Friday, December 13th. They set an “outperform” rating and a $28.00 target price for the company. Finally, Bank of America boosted their price target on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a report on Friday, December 13th.

Stevanato Group Trading Down 1.9 %

Shares of STVN stock opened at €22.06 ($22.74) on Friday. The business has a 50-day moving average of €21.94 and a 200 day moving average of €20.53. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group has a 1-year low of €16.56 ($17.07) and a 1-year high of €34.35 ($35.41). The stock has a market capitalization of $6.68 billion, a PE ratio of 46.94, a P/E/G ratio of 7.76 and a beta of 0.56.

Stevanato Group (NYSE:STVN) last released its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of €0.13 ($0.13) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company had revenue of €277.90 million for the quarter, compared to analysts’ expectations of €274.36 million. During the same period last year, the company posted $0.16 EPS. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Stevanato Group will post 0.5 earnings per share for the current year.

Hedge Funds Weigh In On Stevanato Group

A number of institutional investors have recently bought and sold shares of STVN. Wellington Management Group LLP grew its holdings in shares of Stevanato Group by 4.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,693,588 shares of the company’s stock worth $53,872,000 after acquiring an additional 115,050 shares during the period. Glenmede Trust Co. NA lifted its stake in shares of Stevanato Group by 12.7% in the 3rd quarter. Glenmede Trust Co. NA now owns 35,941 shares of the company’s stock valued at $719,000 after purchasing an additional 4,050 shares during the period. AMI Asset Management Corp bought a new stake in shares of Stevanato Group during the fourth quarter valued at approximately $1,089,000. Raymond James & Associates grew its stake in Stevanato Group by 21.8% in the third quarter. Raymond James & Associates now owns 281,455 shares of the company’s stock worth $5,629,000 after purchasing an additional 50,380 shares during the period. Finally, Natixis Advisors LLC raised its holdings in Stevanato Group by 20.3% in the third quarter. Natixis Advisors LLC now owns 51,343 shares of the company’s stock worth $1,027,000 after purchasing an additional 8,669 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.